- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02107105
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
Prospective Evaluation of Quality of Life and Utilities Following Surgical Treatment of Rectal Cancer
Study Overview
Status
Conditions
- Stage III Rectal Cancer AJCC v8
- Stage IIIA Rectal Cancer AJCC v8
- Stage IIIB Rectal Cancer AJCC v8
- Stage IIIC Rectal Cancer AJCC v8
- Stage IV Rectal Cancer AJCC v8
- Stage IVA Rectal Cancer AJCC v8
- Stage IVB Rectal Cancer AJCC v8
- Stage IVC Rectal Cancer AJCC v8
- Rectal Adenocarcinoma
- Stage IIA Rectal Cancer AJCC v8
- Stage IIB Rectal Cancer AJCC v8
- Stage II Rectal Cancer AJCC v8
- Stage IIC Rectal Cancer AJCC v8
- Stage I Rectal Cancer AJCC v8
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To assess post-treatment related health state utilities among patients with rectal cancer after treatment at 2 years.
SECONDARY OBJECTIVES:
I. To longitudinally compare the effects of treatment on quality of life and utilities among patients treated with or without (neo)adjuvant radiation therapy.
II. To characterize the impact of treatment on quality of life and utilities among patients with rectal cancer.
III. To assess changes in quality of life and utilities among patients treated for rectal cancer over time.
IV. To identify gaps in preoperative counseling for pelvic exenteration by eliciting in-depth insights into patient values, expectations, and lived experiences through qualitative interviews with patients who have undergone surgery for locally advanced or recurrent rectal cancer.
V. To identify themes, communication strategies, and informational content used during preoperative counseling for pelvic exenteration through qualitative interviews with providers.
OUTLINE:
Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: George Chang
- Phone Number: 713-792-6940
- Email: GChang@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Principal Investigator:
- George J. Chang
-
Contact:
- George J. Chang
- Phone Number: 713-792-6940
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient has histologically proven adenocarcinoma of the rectum (stage I - IV) that is planned to be treated by surgical resection performed with curative intent, or who has already received surgical treatment
- Patient must sign an approved informed consent document and have the literary and physical ability to complete the questionnaire in English
Exclusion Criteria:
- Patient has been treated with pelvic radiation therapy for a diagnosis other than rectal cancer
- Patient has a concurrent cancer diagnosis at the time of consent
- Patient has recurrent disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational (questionnaire)
Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
|
Complete quality of life questionnaire
Other Names:
Complete quality of life questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health state utilities
Time Frame: At 24 months post-surgery
|
A health state utility is the degree of preference that individuals or society has for a particular health state or condition.
|
At 24 months post-surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: George J Chang, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-0631 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-07835 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- K07CA133187 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.